Senetek and ICN partner for anaphylactic injector:
This article was originally published in Clinica
Executive Summary
Senetek of Napa, California and ICN Pharmaceuticals of New York, have signed an agreement that gives ICN worldwide rights to AdrenaJect, Senetek's epinephrine filled ReliaJect autoinjector. The device is used by those suffering anaphylactic shock, caused by such events as adverse allergy reactions from insect bites or foods. Senetek will also make available the autoinjector for other therapeutics such as pains management and infertility.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.